SynthesisFrontiers in medicine2026
Obstructive sleep apnoea and glucose dysregulation in type 2 diabetes: a systematic review of the literature.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obstructive sleep apnoea (OSA) and type 2 diabetes mellitus (T2DM) are common chronic conditions with a potentially bidirectional relationship mediated by insulin resistance, intermittent hypoxia, and systemic inflammation. However, evidence linking OSA with glucose dysregulation remains inconsistent. Objective: To evaluate the association between OSA and glucose dysregulation, including prediabetes and T2DM, and related metabolic and cardiovascular outcomes. Methods: A PRISMA-based systematic review was conducted using major databases. Results: In total, eleven studies from Asia, Europe, Africa, and South America were included in this review. The results show that OSA was consistently associated with poorer glycemic control, increased insulin resistance, and adverse metabolic profiles, with several studies demonstrating severity-dependent effects. In addition, poor sleep quality and short sleep duration were also linked to adverse metabolic outcomes, although findings were less consistent. Finally, limited evidence suggested that continuous positive airway pressure (CPAP) therapy may improve some metabolic and renal outcomes. Conclusion: OSA is consistently associated with impaired glucose metabolism and increased cardiometabolic risk in individuals with T2DM. Further longitudinal and interventional studies are needed to clarify causal pathways and the metabolic effects of OSA treatment. Systematic review registration: PROSPERO (CRD420261402284).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.